- Home
- XXI vs ZLAB Comparison
XXI vs ZLAB Comparison
Compare XXI & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XXI | ZLAB |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | United States | China |
| Employees | 3 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | XXI | ZLAB |
|---|---|---|
| Price | $7.35 | $18.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $49.60 |
| AVG Volume (30 Days) | ★ 1.0M | 631.0K |
| Earning Date | 06-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $460,156,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | N/A | $26.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.33 |
| 52 Week Low | $5.61 | $15.96 |
| 52 Week High | $11.49 | $44.34 |
Technical Indicators
Market Signals| Indicator | XXI | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 41.45 | 40.09 |
| Support Level | $5.66 | $18.29 |
| Resistance Level | $7.45 | $19.64 |
| Average True Range (ATR) | 0.40 | 1.02 |
| MACD | -0.17 | -0.22 |
| Stochastic Oscillator | 1.23 | 14.60 |
Price Performance
Historical ComparisonAbout XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc is engaged in the Bitcoin-related business lines. It engages in two principal activities: actively accumulating Bitcoin and managing its Bitcoin holdings, and commencing development of educational materials and branded content intended to drive increased institutional and retail investor Bitcoin literacy.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.